Cargando…

Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study

BACKGROUND AND OBJECTIVES: Subcutaneous immunoglobulin (SCIG) therapy is becoming increasingly popular as self-administration is possible because intravenous access is unnecessary, and there is a lower frequency of systemic adverse events. The aim of this study was to evaluate the shifting from intr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vultaggio, Alessandra, Azzari, Chiara, Milito, Cinzia, Finocchi, Andrea, Toppino, Claudia, Spadaro, Giuseppe, Trizzino, Antonino, Baldassarre, Martire, Paganelli, Roberto, Moschese, Viviana, Soresina, Annarosa, Matucci, Andrea
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2015
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335091/ https://www.ncbi.nlm.nih.gov/pubmed/25672929 http://dx.doi.org/10.1007/s40261-015-0270-1

Ejemplares similares

Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies
por: Canessa, Clementina, et al.
Publicado: (2016)

Biweekly Hizentra® in Primary Immunodeficiency: a Multicenter, Observational Cohort Study (IBIS)
por: Vultaggio, Alessandra, et al.
Publicado: (2018)

Pediatric subset of primary immunodeficiency patients treated with SCIG: post hoc analysis of SHIFT and IBIS pooled data
por: Moschese, Viviana, et al.
Publicado: (2020)

The Italian Registry for Primary Immunodeficiencies (Italian Primary Immunodeficiency Network; IPINet): Twenty Years of Experience (1999–2019)
por: Lougaris, Vassilios, et al.
Publicado: (2020)

The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review
por: Matucci, Andrea, et al.
Publicado: (2018)

Facilitated Subcutaneous Immunoglobulin Treatment in Patients with Immunodeficiencies: the FIGARO Study
por: Borte, Michael, et al.
Publicado: (2023)

Correlations Among Subcutaneous Immunoglobulin Dosage, Immunoglobulin G Serum Pre-infusional Levels and Body Mass Index in Primary Antibody Deficiency Patients: A Pooled Analysis from the SHIFT/IBIS Studies
por: Pecoraro, Antonio, et al.
Publicado: (2020)

Insights into Facilitated Subcutaneous Immunoglobulin Use in Patients with Secondary Immunodeficiency Diseases: A FIGARO Subgroup Analysis
por: Dimou, Maria, et al.
Publicado: (2023)

Different Degrees of NADPH Oxidase 2 Regulation and In Vivo Platelet Activation: Lesson From Chronic Granulomatous Disease
por: Carnevale, Roberto, et al.
Publicado: (2014)

Progressive Depletion of B and T Lymphocytes in Patients with Ataxia Telangiectasia: Results of the Italian Primary Immunodeficiency Network
por: Cirillo, Emilia, et al.
Publicado: (2022)

The Impact of SARS-CoV-2 Infection in Patients with Inborn Errors of Immunity: the Experience of the Italian Primary Immunodeficiencies Network (IPINet)
por: Giardino, Giuliana, et al.
Publicado: (2022)

Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies
por: Cinetto, Francesco, et al.
Publicado: (2021)

Serum Free Light Chains in Common Variable Immunodeficiency Disorders: Role in Differential Diagnosis and Association With Clinical Phenotype
por: Scarpa, Riccardo, et al.
Publicado: (2020)

Clinical outcome, incidence, and SARS-CoV-2 infection-fatality rates in Italian patients with inborn errors of immunity
por: Milito, Cinzia, et al.
Publicado: (2021)

Novel artful applications of vaccines at the horizon
por: Montin, Davide, et al.
Publicado: (2022)

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia
por: Quinti, Isabella, et al.
Publicado: (2020)

Intergenerational and intrafamilial phenotypic variability in 22q11.2 Deletion syndrome subjects
por: Cirillo, Emilia, et al.
Publicado: (2014)

High Serum β-Lactams Specific/Total IgE Ratio Is Associated with Immediate Reactions to β-Lactams Antibiotics
por: Vultaggio, Alessandra, et al.
Publicado: (2015)

Mechanisms of Action of Ig Preparations: Immunomodulatory and Anti-Inflammatory Effects
por: Matucci, Andrea, et al.
Publicado: (2015)

Hyaluronidase facilitated subcutaneous immunoglobulin in primary immunodeficiency
por: Jolles, Stephen
Publicado: (2013)

Case Report: A child with NFKB1 haploinsufficiency explaining the linkage between immunodeficiency and short stature
por: Ricci, S., et al.
Publicado: (2023)

Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?
por: Matucci, Andrea, et al.
Publicado: (2018)

Long term longitudinal follow-up of an AD-HIES cohort: the impact of early diagnosis and enrollment to IPINet centers on the natural history of Job’s syndrome
por: Carrabba, Maria, et al.
Publicado: (2023)

Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors
por: Matucci, Andrea, et al.
Publicado: (2021)

Is It Safe to Switch From Intravenous Immunoglobulin to Subcutaneous Immunoglobulin in Patients With Common Variable Immunodeficiency and Autoimmune Thrombocytopenia?
por: Scheuerlein, Philipp, et al.
Publicado: (2018)

Subcutaneous immunoglobulin replacement therapy in the treatment of patients with primary immunodeficiency disease
por: Skoda-Smith, Suzanne, et al.
Publicado: (2010)

New Frontiers in Subcutaneous Immunoglobulin Treatment
por: Jolles, Stephen, et al.
Publicado: (2011)

Use of subcutaneous immunoglobulin in inflammatory myositis
por: Zhou, Alan L, et al.
Publicado: (2021)

Case Report: EBV Chronic Infection and Lymphoproliferation in Four APDS Patients: The Challenge of Proper Characterization, Therapy, and Follow-Up
por: Rivalta, Beatrice, et al.
Publicado: (2021)

B Cell Responses to CpG Correlate with CXCL16 Expression Levels in Common Variable Immunodeficiency
por: Lougaris, Vassilios, et al.
Publicado: (2012)

Effects of Body Mass and Age on the Pharmacokinetics of Subcutaneous or Hyaluronidase-facilitated Subcutaneous Immunoglobulin G in Primary Immunodeficiency Diseases
por: Li, Zhaoyang, et al.
Publicado: (2023)

Primary Immunodeficiencies and Oncological Risk: The Experience of the Children's Hospital of Brescia
por: Maffeis, Marianna, et al.
Publicado: (2019)

Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases
por: Kobrynski, Lisa
Publicado: (2012)

Initiation of immunoglobulin therapy by subcutaneous administration in immunodeficiency patients naive to replacement therapy
por: Koterba, Alan P, et al.
Publicado: (2014)

Subcutaneous immunoglobulin therapy for adult patients with primary immunodeficiency disease: Qatar experience
por: Thalappil, Sherin, et al.
Publicado: (2023)

Health-Related Quality of Life in Patients with CVID Under Different Schedules of Immunoglobulin Administration: Prospective Multicenter Study
por: Pulvirenti, Federica, et al.
Publicado: (2019)

Mechanisms of Drug Desensitization: Not Only Mast Cells
por: Vultaggio, Alessandra, et al.
Publicado: (2020)

How to Prevent and Mitigate Hypersensitivity Reactions to Biologicals Induced by Anti-Drug Antibodies?
por: Vultaggio, Alessandra, et al.
Publicado: (2021)

Targeted NGS Platforms for Genetic Screening and Gene Discovery in Primary Immunodeficiencies
por: Cifaldi, Cristina, et al.
Publicado: (2019)

Positive effect of erythrocyte-delivered dexamethasone in ataxia-telangiectasia
por: Leuzzi, Vincenzo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_kd9vv06rm3po8cu3tsk5pdik0t